Compare Biocon Ltd with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SANOFI INDIA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SANOFI INDIA BIOCON /
SANOFI INDIA
 
P/E (TTM) x 17.0 34.5 49.3% View Chart
P/BV x 2.6 6.0 43.5% View Chart
Dividend Yield % 0.4 1.4 30.5%  

Financials

 BIOCON    SANOFI INDIA
EQUITY SHARE DATA
    BIOCON
Mar-18
SANOFI INDIA
Dec-18
BIOCON /
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,1886,840 17.4%   
Low Rs3054,630 6.6%   
Sales per share (Unadj.) Rs68.71,203.1 5.7%  
Earnings per share (Unadj.) Rs7.6165.3 4.6%  
Cash flow per share (Unadj.) Rs14.0209.9 6.7%  
Dividends per share (Unadj.) Rs1.0084.00 1.2%  
Dividend yield (eoy) %0.11.5 9.1%  
Book value per share (Unadj.) Rs86.3963.6 9.0%  
Shares outstanding (eoy) m600.0023.03 2,605.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.8 227.9%   
Avg P/E ratio x98.934.7 284.9%  
P/CF ratio (eoy) x53.427.3 195.5%  
Price / Book Value ratio x8.66.0 145.3%  
Dividend payout %13.250.8 26.1%   
Avg Mkt Cap Rs m447,900132,078 339.1%   
No. of employees `0006.13.3 186.3%   
Total wages/salary Rs m9,3114,068 228.9%   
Avg. sales/employee Rs Th6,705.88,393.8 79.9%   
Avg. wages/employee Rs Th1,514.21,232.4 122.9%   
Avg. net profit/employee Rs Th736.91,153.0 63.9%   
INCOME DATA
Net Sales Rs m41,23427,708 148.8%  
Other income Rs m2,062897 229.9%   
Total revenues Rs m43,29628,605 151.4%   
Gross profit Rs m8,2916,235 133.0%  
Depreciation Rs m3,8511,027 375.0%   
Interest Rs m6157 8,785.7%   
Profit before tax Rs m5,8876,098 96.5%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5692,292 68.5%   
Profit after tax Rs m4,5313,806 119.0%  
Gross profit margin %20.122.5 89.4%  
Effective tax rate %26.737.6 70.9%   
Net profit margin %11.013.7 80.0%  
BALANCE SHEET DATA
Current assets Rs m41,48615,922 260.6%   
Current liabilities Rs m21,4136,235 343.4%   
Net working cap to sales %48.735.0 139.2%  
Current ratio x1.92.6 75.9%  
Inventory Days Days6464 100.5%  
Debtors Days Days9421 451.3%  
Net fixed assets Rs m50,6617,539 672.0%   
Share capital Rs m3,000230 1,304.3%   
"Free" reserves Rs m48,80821,962 222.2%   
Net worth Rs m51,80822,192 233.5%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89729,839 334.8%  
Interest coverage x10.6872.1 1.2%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.40.9 44.5%   
Return on assets %5.212.8 40.3%  
Return on equity %8.717.2 51.0%  
Return on capital %9.627.5 35.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,0587,587 158.9%   
Fx outflow Rs m7,3487,145 102.8%   
Net fx Rs m4,710442 1,065.6%   
CASH FLOW
From Operations Rs m6,6213,739 177.1%  
From Investments Rs m-6,840-731 935.7%  
From Financial Activity Rs m-2,397-1,972 121.6%  
Net Cashflow Rs m-2,6121,036 -252.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 60.4 34.1%  
Indian inst/Mut Fund % 8.4 14.4 58.3%  
FIIs % 10.7 14.6 73.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 15,184 724.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  GLENMARK PHARMA  SUVEN LIFESCIENCES  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Sep 18, 2019 03:33 PM

TRACK BIOCON

BIOCON - ABBOTT INDIA COMPARISON

COMPARE BIOCON WITH

MARKET STATS